Scientific program

Friday, February 5th
8:30 h Introduction
A. Artigas, MD (Sabadell, Spain)
J. Carlet, MD (Paris, France)
M. Niederman, MD (Mineola, USA)
A. Torres, MD (Barcelona, Spain)
I SEPSIS
Moderators A. Artigas, MD (Sabadell, Spain)
J. Cohen, MD (Brighton, UK)
8:45h Sepsis: The Old and New Players Update.
JL. Vincent, MD (Brussels, Belgium)
9:15h Reducing Mortality in Sepsis: The International Surviving Sepsis
M. Levy, MD (Rhode Island, USA)
9:35h Myocardial Dysfunction in Sepsis.
JL. Teboul, MD (Paris, France)
9:55h Glycemic Control in Sepsis: Too Loose, Too Tight, Just Right?
K. Reinhart, MD (Jena, Germany)
10:15h Coffee-break
10:45h The Epic II Study
J.L. Vincent, MD (Brussels, Belgium)
11:05h Biomarkers in Sepsis I: Can We Use Them in Guiding Sepsis Therapy?
H. Gerlach, MD PhD (Berlin, Germany)
11:25h The Elderly Patient Admitted to the ICU with Sepsis.
Ch. Sprung, MD (Jerusalem, Israel)
11:45h Improving Clinical Trials in Sepsis.
J. Cohen, MD (Brighton, UK)
12:05h Debate: Should We Use Statins in Sepsis?
Moderator: J. Pugin, MD (Genève, Switzerland)
Pro: J. Garnacho, MD (Sevilla, Spain)
Con: R. Fernández, MD (Manresa, Spain)
13:30h Meet the Expert Session (lunch included)
   
II BASIC RESEARCH AND EPIDEMIOLOGY OF SEVERE INFECTIONS
Moderators E. Abraham, MD (Birmingham, USA)
T. Calandra, MD (Lausanne, Switzerland)
15:00h

 Biomarkers in Sepsis II: Can We Use Them in Staging?
M. Levy, MD (Rhode Island, USA)
15:20h
 Endotoxin Renoval. Is a Real Option?
M. Antonelli, MD (Rome, Italy)
15:40h
 Failure of Bioenergetics Pathways in Sepsis.
M. Singer, MD (London, UK)
16:00h
 Acquired Inmunosupression in Severe Sepsis.
J.D. Chiche, MD (Paris, France)
16:20h
 Coffee-break
16:50h
 The Importance of Apoptosis in Sepsis.
E. Abraham, MD (Birmingham, USA)
17:10h
 Present Understanding of Genetics and Outcome for Severe Infections.
T. Calandra, MD (Lausanne, Switzerland)
17:30h Mechanical Stress and Endothelial Barrier Function:
Mechanisms and Therapeutic Implications for Sepsis and Lung Injury.
J. Pugin, MD(Genève, Switzerland)
 
Saturday, February 6th
III PULMONARY INFECTIONS
Moderators:

A. Torres, MD (Barcelona, Spain)
M. Antonelli, MD (Rome, Italy)
8:30h
 Use of Surveillance Cultures and Biomedical Tests in VAP.
J. Chastre, MD (Paris, France)
8:50h
 What We Learn on Animal Models of VAP.
A. Torres, MD (Barcelona, Spain)
9:10h
 Mechanical Ventilation with PEEP: The Effect on VAP.
GL. Libassi, MD (Barcelona, Spain)
9:30h
 Ventilator-Associated Tracheobronchitis.
D. Craven, MD (Boston, USA)
9:50h
 Proceedings of the FDA for Design of VAP Trials
M. Niederman, MD (Mineola, USA)
10:10h
 Coffee-break
10:40h
 Candida Colonization of Respiratory Tract in Ventilated Patients?
A. Paiva, MD (Porto, Portugal)
11:00h
 SDD: The Final Answer.
M. Sánchez, MD (Madrid, Spain)
11:20h
 Steroids for Severe CAP.
P. Povoa, MD (Lisboa, Portugal)
11:40h
 How to Prevent VAP
M. Kollef, MD (St. Louis, USA)
12:00h
 Should Hospital Be Paid for Nosocomial Infections?
M. Niederman, MD (Mineola, USA)
12:20h

Debate: Are Guidelines Useful for Pneumonia Managament?
Moderator: E. Bouza, MD (Madrid, Spain)
Pro: A. Torres, MD (Barcelona, Spain)
Con: M. Kollef, MD (St. Louis, USA)
13:00h
Symposium Janssen- Cilag (lunch included)
 
IV TREATMENT AND PROPHYLAXIS
Moderators

M. Niederman, MD (Mineola, USA)
J. Carlet, MD (Paris, France)
14:30h
 Critical Care New Biomedical Devices: It’s Impact on Infections.
M. Kollef, MD (St. Louis, USA)
14:50h
 New Antifungal Agent
T. Calandra, MD (Lausanne, Switzerland)
15:10h
 New Antibacterial and Anti-toxin Strategies for Severe Infections.
J. Carlet, MD (Paris, France)
15:30h
 Coffee-break
16:00h
 Use of Antibiotics to Minimize Antibiotics Resistance.
H. Giamarellou, MD (Athens, Greece)
16:20h
 EarlyDiagnosis of Catheter Related Infection.
E. Bouza, MD (Madrid, Spain)
17:00h
 Preventing Bloodstream Infections in Critically Ill Patients.
M. Palomar, MD (Barcelona, Spain)
17:20h Closing Remarks